retatrutide triple agonist gip glp-1 glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide peptide for weight loss
Pay in 4 interest-free payments of $6.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17












:max_bytes(150000):strip_icc()/VWH-AmeliaManley-OzempicvsWegovyvsMounjaro-dc80b8c8de6243ec9b984cd4b5db5db4.jpg)











